Atyr PHARMA (NASDAQ:ATYR - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Atyr PHARMA Price Performance
NASDAQ:ATYR traded up $0.26 during trading hours on Friday, reaching $3.60. The company had a trading volume of 1,375,066 shares, compared to its average volume of 905,107. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $3.29 and a two-hundred day moving average of $3.40. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The firm has a market capitalization of $319.89 million, a PE ratio of -3.83 and a beta of 0.95.
Wall Street Analyst Weigh In
ATYR has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partners initiated coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an "overweight" rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA currently has an average rating of "Buy" and an average price target of $18.60.
Check Out Our Latest Report on Atyr PHARMA
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
